Grades 3 to 4 toxic effects of thalidomide in patients with newly diagnosed MM
| Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
|---|---|---|---|---|---|---|
| Dexamethasone | ||||||
| TD | 235 | 1 | 3 | ND | 2 | 52*† |
| TD | 103 | ND | ND | 7 | 7 | 31* |
| TD | 100 | ND | 0 | 4 | 4 | 32 |
| TD | 50 | ND | ND | ND | 2 | 30 |
| TD | 100 | ND | ND | ND | ND | 33* |
| Melphalan | ||||||
| MPT | 129 | 3 | 16 | 10 | 8 | 37* |
| MPT | 125 | 14 | 48 | 13 | 6 | 38* |
| MPT | 113 | ND | 23‡ | ND | 20‡ | 39* |
| Doxorubicin | ||||||
| ThaDD | 50 | 0 | 12 | 22 | 0 | 44 |
| T-VAD doxil | 117 | 8‡ | 10‡ | 7 | 6‡ | 45* |
| T-VAD doxil | 39 | 15 | 15 | 21 | 5 | 40 |
| Cyclophosphamide, CTD | 27 | ND | 4 | 7 | 4 | 47 |
| Regimen . | No. patients . | Thrombocytopenia, % . | Neutropenia, % . | Infection, % . | Peripheral neuropathy, % . | Reference . |
|---|---|---|---|---|---|---|
| Dexamethasone | ||||||
| TD | 235 | 1 | 3 | ND | 2 | 52*† |
| TD | 103 | ND | ND | 7 | 7 | 31* |
| TD | 100 | ND | 0 | 4 | 4 | 32 |
| TD | 50 | ND | ND | ND | 2 | 30 |
| TD | 100 | ND | ND | ND | ND | 33* |
| Melphalan | ||||||
| MPT | 129 | 3 | 16 | 10 | 8 | 37* |
| MPT | 125 | 14 | 48 | 13 | 6 | 38* |
| MPT | 113 | ND | 23‡ | ND | 20‡ | 39* |
| Doxorubicin | ||||||
| ThaDD | 50 | 0 | 12 | 22 | 0 | 44 |
| T-VAD doxil | 117 | 8‡ | 10‡ | 7 | 6‡ | 45* |
| T-VAD doxil | 39 | 15 | 15 | 21 | 5 | 40 |
| Cyclophosphamide, CTD | 27 | ND | 4 | 7 | 4 | 47 |